Progressive Multifocal Leukoencephalopathy – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Progressive Multifocal Leukoencephalopathy – Pipeline Review, H1 2020’, provides an overview of the Progressive Multifocal Leukoencephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy

– The report reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Progressive Multifocal Leukoencephalopathy therapeutics and enlists all their major and minor projects

– The report assesses Progressive Multifocal Leukoencephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Progressive Multifocal Leukoencephalopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biological E Ltd

Evrys Bio

Excision BioTherapeutics Inc

Humabs BioMed SA

Inhibikase Therapeutics Inc

Neurimmune Holding AG

Pomona Ricerca SRL

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Progressive Multifocal Leukoencephalopathy - Overview

Progressive Multifocal Leukoencephalopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development

Biological E Ltd

Evrys Bio

Excision BioTherapeutics Inc

Humabs BioMed SA

Inhibikase Therapeutics Inc

Neurimmune Holding AG

Pomona Ricerca SRL

Progressive Multifocal Leukoencephalopathy - Drug Profiles

EBT-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IkT-01427 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for John Cunningham Infections and Progressive Multifocal Leukoencephalopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNJC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Progressive Multifocal Leukoencephalopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Progressive Multifocal Leukoencephalopathy - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Progressive Multifocal Leukoencephalopathy – Pipeline by Biological E Ltd, H1 2020

Progressive Multifocal Leukoencephalopathy – Pipeline by Evrys Bio, H1 2020

Progressive Multifocal Leukoencephalopathy – Pipeline by Excision BioTherapeutics Inc, H1 2020

Progressive Multifocal Leukoencephalopathy – Pipeline by Humabs BioMed SA, H1 2020

Progressive Multifocal Leukoencephalopathy – Pipeline by Inhibikase Therapeutics Inc, H1 2020

Progressive Multifocal Leukoencephalopathy – Pipeline by Neurimmune Holding AG, H1 2020

Progressive Multifocal Leukoencephalopathy – Pipeline by Pomona Ricerca SRL, H1 2020

Progressive Multifocal Leukoencephalopathy – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports